Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Dhruv Prajapati"'
Autor:
Sean Monemi, Jonathan Aviles, Eric Oliver, Dhruv Prajapati, Michael Nava, Jon-Michael Brown, Spencer Robinson
Publikováno v:
2023 IEEE Conference on Technologies for Sustainability (SusTech).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::044b9526c217916cc76cc2e17e8e8aa4
https://doi.org/10.1109/sustech57309.2023.10129571
https://doi.org/10.1109/sustech57309.2023.10129571
Publikováno v:
Sustainable Water Resources Management. 9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fb665af6c8e65e32857178788dfaa59
https://doi.org/10.1007/s40899-023-00853-y
https://doi.org/10.1007/s40899-023-00853-y
Autor:
Yash Dara, Sumanta K. Pal, Matthew Feng, Nicholas Salgia, Dhruv Prajapati, Nora Ruel, Meghan Salgia, Michael Nissanoff, Richard Harwood
Publikováno v:
Kidney Cancer. 4:103-109
BACKGROUND: Twitter has emerged as an important platform for conversation surrounding cancer-related topics. As use has proliferated, a better classification of physicians engaging in cancer discussions on Twitter is warranted. OBJECTIVES: To better
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d8ad31e0496452e8e542661937be6c0
https://doi.org/10.3233/kca-200083
https://doi.org/10.3233/kca-200083
Publikováno v:
Cancer treatment and research. 175
The treatment landscape for metastatic renal cell carcinoma has constantly been in flux. In 2005, with the advent of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) therapy, the standard of care shifted to agents such as sun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a440394a31eb12cef4c54b1f9a165843
https://pubmed.ncbi.nlm.nih.gov/30168120
https://pubmed.ncbi.nlm.nih.gov/30168120
Autor:
Paulo Gustavo Bergerot, Rachel Fox, Sumanta K. Pal, Kathy Burns, Dhruv Prajapati, Meghan Salgia
Publikováno v:
Cancer Treatment and Research ISBN: 9783319933382
The treatment landscape for metastatic renal cell carcinoma has constantly been in flux. In 2005, with the advent of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) therapy, the standard of care shifted to agents such as sun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c13c0444c24552003da28140821c180d
https://doi.org/10.1007/978-3-319-93339-9_6
https://doi.org/10.1007/978-3-319-93339-9_6
